Aprepitant (Emend)

A morpholine neurokinin-1 (NK1) receptor antagonist that is used in the management of nausea and vomiting caused by DRUG THERAPY, and for the prevention of POSTOPERATIVE NAUSEA AND VOMITING.

Also Known As:

Emend; (1-(3,5-bis(Trifluoromethyl)phenyl)ethoxy)-3-(fluoro)phenyl-4-(3-oxo-1,2,4-triazol-5-yl)methylmorpholine; (2R)-(1R)-3,5-bis(Trifluoromethylphenyl)ethoxy)-(3S)-(4-fluoro)phenyl-4-(3-(5-oxo-1H,4H-1,2,4-triazole)methyl-morpholine; L 754,030; L 754030; L-754,030; L-754030; MK 0517; MK 0869; MK 869; MK-0517; MK-0869; MK-869; MK0517; L754,030; L754030; MK0869; MK869; 3H-1,2,4-Triazol-3-one, 5-(((2R,3S)-2-((1R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl)-4-morpholinyl)methyl)-2,4-dihydro-

Networked: 725 relevant articles (194 outcomes, 237 trials/studies)

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Oxazines: 9
    - Morpholines: 6
      - Aprepitant: 725

Experts

1.	Muñoz, Miguel: 18 articles (10/2022 - 04/2010)
2.	Navari, Rudolph M: 16 articles (08/2021 - 06/2002)
3.	Coveñas, Rafael: 15 articles (10/2022 - 08/2010)
4.	Carides, Alexandra D: 14 articles (02/2013 - 06/2002)
5.	Hesketh, Paul J: 12 articles (01/2017 - 05/2003)
6.	Evans, Judith K: 12 articles (02/2009 - 06/2002)
7.	Petty, Kevin J: 11 articles (07/2006 - 05/2003)
8.	Gralla, Richard J: 10 articles (01/2017 - 05/2003)
9.	Hashemy, Seyed Isaac: 9 articles (06/2022 - 06/2020)
10.	Douglas, Steven D: 9 articles (06/2021 - 03/2007)

Related Diseases

1.	Vomiting 07/01/2011 - "Vomiting was dramatically reduced by the concomitant administration of aprepitant. " 06/01/2011 - "Aprepitant markedly improved control of emesis in patients with one or more risk factors. " 04/01/2010 - "The aprepitant regimen provided superior efficacy in the treatment of CINV in a broad range of patients receiving MEC (non-AC or AC) in both no vomiting and complete response endpoints. " 12/01/2013 - "To investigate efficacy of aprepitant in children and young adolescents with high or moderate emetogenic courses, with uncontrollable emesis in previous cycles. " 12/01/2013 - "Aprepitant might be effective in preventing or reducing vomiting in children. "
2.	Nausea 02/01/2012 - "Multiple-day dosing of aprepitant was effective for prevention of nausea(Odds ratio: 0. " 10/11/2016 - "Of 57 patients, 52 reported that the addition of aprepitant improved nausea. " 01/01/2021 - "Only one study that compared aprepitant plus 5-HT3RA with 5-HT3RA, concluded that the addition of aprepitant reduced the incidence of severe nausea, and it might also provide an economic benefit in the overall management. " 01/01/2023 - "The absolute plasma concentration of free ND-AP was higher in patients without the delayed nausea, and its concentration to determine the occurrence was 18.9 ng/mL. The occurrence of delayed nausea had no relation with absolute plasma aprepitant. " 06/01/2020 - "Aprepitant is currently used in clinical practice as an anti-nausea medication."
3.	Postoperative Nausea and Vomiting (PONV) 01/01/2023 - "Aprepitant is effective for PONV prophylaxis. " 05/01/2015 - " data suggested that NK-1R antagonists, especially aprepitant were effective in preventing PONV compared with placebo. " 01/01/2009 - "A single oral dose of aprepitant 40 mg administered prior to patients undergoing abdominal surgery was also effective in the prevention of postoperative nausea and vomiting (PONV). " 12/01/2023 - "Multivariate analysis demonstrated that aprepitant decreased the incidence of postoperative vomiting with odds ratio of 0.107. " 07/21/2023 - "This meta-analysis aimed to explore the efficacy of aprepitant for preventing PONV based on the existing literature. "
4.	Neoplasms (Cancer) 05/23/2023 - "This study aimed to investigate the anti-tumor activity of aprepitant on GBC and the potential mechanisms. " 01/01/2023 - "Studies with NK-1R antagonists (such as aprepitant) denote that the NK-1R is a potential target for the treatment of cancer. " 10/01/2021 - "This pragmatic study in patients with cancer receiving AC and non-AC MEC revealed that a single dose of oral NEPA plus DEX was at least as effective as a 3-day aprepitant regimen, with indication of a potential efficacy benefit for NEPA. " 09/20/2020 - "In in vivo and in vitro studies, aprepitant also showed the aforementioned multiple antitumor actions against many types of cancer. " 04/01/2010 - "This study assessed aprepitant in patients receiving a broad range of MEC regimens with a variety of tumor types. "
5.	Breast Neoplasms (Breast Cancer) 10/01/2014 - "No in-depth studies of the involvement of this system in breast cancer (BC) have been carried out, and the action exerted by the drug aprepitant on BC cells is currently unknown. " 02/01/2009 - "This is a single center, randomized, double-blind placebo-controlled study to evaluate the NK(1)-receptor antagonist, aprepitant, in Chinese breast cancer patients. " 08/01/2011 - "[Efficacy and safety of aprepitant in patients with breast cancer]." 01/01/2013 - "The results of this study suggest that aprepitant is cost-effective for preventing CINV associated with chemotherapy for patients with breast cancer in the UK health care setting." 02/01/2013 - "For MEC-treated patients, complete response rates were also higher for aprepitant patients than active-control patients for all tumor types, with a significant difference noted among patients with breast cancer (54.9% vs 43.9%, P<0.0001). "

Related Drugs and Biologics

1.	Dexamethasone (Maxidex)
2.	Antiemetics
3.	Cisplatin (Platino)
4.	Palonosetron (Aloxi)
5.	Ondansetron (Zofran)
6.	Neurokinin-1 Receptor Antagonists
7.	Adrenal Cortex Hormones (Corticosteroids)
8.	5-HT3 Serotonin Receptors (5 HT3 Receptor)
9.	Granisetron (Kytril)
10.	Serotonin (5 Hydroxytryptamine)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics
3.	Salvage Therapy
4.	Combination Drug Therapy (Combination Chemotherapy)
5.	Radiotherapy